Do Kim
Stock Analyst at Piper Sandler
(1.92)
# 3,040
Out of 4,752 analysts
98
Total ratings
44%
Success rate
0.56%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $31.76 | +98.39% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $20.40 | +125.49% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $471.62 | -37.24% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $98.13 | +14.13% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $25.23 | +244.90% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $4.37 | +426.32% | 2 | Jan 19, 2023 | |
| AFMD Affimed | Maintains: Overweight | $70 → $60 | $1.00 | +5,900.00% | 6 | Dec 12, 2022 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $20.83 | -3.98% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $13.52 | +218.05% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $33.15 | -3.47% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $3.14 | +600.66% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $39.94 | -52.43% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.25 | +611.62% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $275.07 | -32.74% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $10.67 | +8,334.86% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $56.45 | -38.00% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.25 | +1,500.00% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $31.76
Upside: +98.39%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $20.40
Upside: +125.49%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $471.62
Upside: -37.24%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $98.13
Upside: +14.13%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $25.23
Upside: +244.90%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $4.37
Upside: +426.32%
Affimed
Dec 12, 2022
Maintains: Overweight
Price Target: $70 → $60
Current: $1.00
Upside: +5,900.00%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $20.83
Upside: -3.98%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $13.52
Upside: +218.05%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $33.15
Upside: -3.47%
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.14
Upside: +600.66%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $39.94
Upside: -52.43%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $2.25
Upside: +611.62%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $275.07
Upside: -32.74%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $10.67
Upside: +8,334.86%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $56.45
Upside: -38.00%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.25
Upside: +1,500.00%